v3.26.1
Segment
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Segment
The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance. The Company has a single reporting unit associated with the development and commercialization of diagnostic tests and biopharmaceutical services. The accounting policies of the Company's single segment are the same as those described in the summary of significant accounting policies in Note 1, Organization, Description of Business and Summary of Significant Accounting Policies. The chief operating decision maker assesses performance of the Company's single segment and decides how to allocate resources based on consolidated net income. Under the current organizational structure, this measure is not discretely available or required individually for any of the Company’s business activities and is only available at the consolidated level. The monitoring of budgeted versus actual results are used in assessing performance of the Company's single segment, allocating resources and in establishing management’s compensation. The Company's chief operating decision maker intends for all revenue generating activities to rely on cross-functional activities across the consolidated entity in order to operate. No individual besides the chief operating decision maker has been tasked with reviewing discrete operating results of the business activities, nor is there any intent to bifurcate the overall business review process to produce discrete operating results specific to any of the Company's business activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Consolidated revenue does not include any inter-segment sales or transfers.
Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):

Three Months Ended March 31,
20262025
Revenue:
Testing revenue$135,091 $107,309 
Product revenue3,679 3,580 
Biopharmaceutical and other revenue301 3,584 
Total revenue139,071 114,473 
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense12,314 13,067 
Sample collection expense3,288 2,825 
Compensation expense9,804 5,611 
Other cost of testing revenue (1)4,937 3,385 
Allocation of facilities and IT expenses2,963 3,372 
Total cost of testing revenue33,306 28,260 
Cost of product revenue:
Product costs1,401 109 
License fees and royalties313 324 
Other cost of product revenue (2)174 792 
Allocation of facilities and IT expenses3 197 
Total cost of product revenue1,891 1,422 
Cost of biopharmaceutical and other revenue:
Compensation expense— 1,240 
Other cost of biopharmaceutical and other revenue (3)8 1,044 
Allocation of facilities and IT expenses— 414 
Total cost of biopharmaceutical and other revenue8 2,698 
Intangible asset amortization - cost of revenue2,707 2,585 
Gross profit101,159 79,508 
Operating expenses:
Research and development:
Compensation expense15,547 9,748 
Direct research and development expense4,198 4,141 
Other research and development expenses (4)5,460 1,815 
Allocation of facilities and IT expenses1,893 2,016 
Total research and development27,098 17,720 
Selling and marketing:
Compensation expense19,972 17,635 
Direct marketing expense1,455 710 
Other selling and marketing expenses (5)4,561 3,853 
Allocation of facilities and IT expenses1,168 2,256 
Total selling and marketing27,156 24,454 
General and administrative:
Compensation expense16,236 20,173 
Other general and administrative expenses (6)13,471 21,890 
Allocation of facilities and IT expenses(6,027)(8,255)
Total general and administrative23,680 33,808 
Intangible asset amortization - operating expenses579 622 
Other income, net(7,328)(4,524)
Income tax provision1,267 381 
Net income$28,707 $7,047 
________________
(1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses.
(2)Other cost of product revenue includes contract manufacturing fees, license fees and royalties, depreciation and amortization and other expenses.
(3)Other cost of biopharmaceutical and other revenue includes professional fees, information technology expense, depreciation and amortization and other expenses.
(4)Other research and development expenses include depreciation and amortization and other expenses.
(5)Other selling and marketing expenses include travel, entertainment, conference and other expenses.
(6)Other general and administrative expenses include professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.